Stay up to date with the latest developments in therapeutics by reading the world’s most respected source of authoritative drug information. For 50 years Drugs has been the definitive journal of drugs and therapeutics, promoting optimum pharmacotherapy by publishing reviews and original research authored by leading international clinicians and researchers to support clinical decision-making.   

Through a rigorous and comprehensive program of peer-reviewed evaluations, Drugs provides detailed and objective analysis covering the full spectrum of new and established drug therapies in all disease areas.

As a hybrid journal, Drugs does not charge authors to publish using the traditional subscription-based publishing route, but does offer the option to publish accepted articles open access if authors so wish or if their funders require. This is achieved via the Springer Open Choice™ initiative. More information about this optional route to open access and the associated article processing charge can be found by clicking on the ‘How to publish with us, including Open Access’ link below.

Drugs offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.

Journal information

Editor
  • Dene Peters
Publishing model
Hybrid. How to publish with us, including Open Access

Journal metrics

9.546 (2020)
Impact factor
7.641 (2020)
Five year impact factor
8 days
Submission to first decision (Median)
975,922 (2021)
Downloads

Latest articles

Journal updates

View all updates

About this journal

Electronic ISSN
1179-1950
Print ISSN
0012-6667
Abstracted and indexed in
  1. BFI List
  2. BIOSIS
  3. Baidu
  4. CAB Abstracts
  5. CLOCKSS
  6. CNKI
  7. CNPIEC
  8. Chemical Abstracts Service (CAS)
  9. Current Contents/ Life Sciences
  10. Current Contents/Clinical Medicine
  11. Dimensions
  12. EBSCO Academic Search
  13. EBSCO Advanced Placement Source
  14. EBSCO Biomedical Reference Collection
  15. EBSCO CINAHL
  16. EBSCO Discovery Service
  17. EBSCO Nursing and Allied Health Collection
  18. EBSCO Rehabilitation & Sports Medicine Source
  19. EBSCO SPORTDiscus
  20. EBSCO STM Source
  21. EBSCO Science & Technology Collection
  22. EMBASE
  23. EMBiology
  24. EMCare
  25. Google Scholar
  26. Japanese Science and Technology Agency (JST)
  27. Journal Citation Reports/Science Edition
  28. Medline
  29. Naver
  30. OCLC WorldCat Discovery Service
  31. Pathway Studio
  32. Portico
  33. ProQuest-ExLibris Primo
  34. ProQuest-ExLibris Summon
  35. Reaxys
  36. SCImago
  37. SCOPUS
  38. Science Citation Index Expanded (SCIE)
  39. Semantic Scholar
  40. TD Net Discovery Service
  41. UGC-CARE List (India)
  42. Wanfang
Copyright information

Rights and permissions

Springer policies

© Springer Nature Switzerland AG